We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Germline and Somatic Variants Analyzed in Ovarian Cancer

By LabMedica International staff writers
Posted on 06 Feb 2014
Print article
Image: Photomicrograph of solid ovarian carcinoma (Photo courtesy of University of Guelph).
Image: Photomicrograph of solid ovarian carcinoma (Photo courtesy of University of Guelph).
Genetic studies of inherited predisposition to ovarian cancer have tended to focus on women with a known family history of the disease.

For ovarian cancer patients with no known family history of the disease it has been found that one fifth of them had inherited alterations in genes known to be linked to ovarian and breast cancer.

Scientists at Washington University School of Medicine (St. Louis, MO, USA) working with colleagues from other institutes, studied 429 women with sporadic ovarian cancer who did not have a known family history of either ovarian or breast cancer or rare cancer syndromes, all of which are known to increase the risk of developing ovarian tumors. They analyzed DNA from each woman's tumor tissue and compared it with DNA from her skin. From this comparison, they could identify the acquired mutations in each tumor. They also compared the patients' skin DNA with that of 557 women without ovarian cancer to identify inherited mutations.

In total, the team found 222 inherited mutations that increase the risk for ovarian cancer. Some were already known about, for instance breast cancer 1, early onset (BRCA1) and BRCA2, while others have never been linked to ovarian cancer. They identified 3,635 high confidence, rare truncation, and 22,953 missense variants with predicted functional impact. They found germline truncation variants and large deletions across Fanconi pathway genes in 20% of cases. Enrichment of rare truncations was shown in BRCA1, BRCA2, and the gene Partner and Localizer of BRCA2 (PALB2). Evidence for loss of heterozygosity was found in 100% and 76% of cases with germline BRCA1 and BRCA2 truncations, respectively.

Li Dang, PhD, the senior author of the study, said, “Using advanced genomic analysis, we found that 20% of women with ovarian cancer had inherited mutations in a gene pathway known to be important in inherited breast and ovarian cancer. This number is pretty high and we need to find better ways to screen women for ovarian cancer, even if they don't have family histories of the disease.” The study was published on January 22, 2014, in the journal Nature Communications.

Related Links:

Washington University School of Medicine


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Troponin T QC
Troponin T Quality Control
New
Hepatitis B Test
OnSite HBsAg Rapid Test
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA

Print article

Channels

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.